StockData

Liminatus Pharma, Inc. (LIMNW) stock analysis

LIMNWNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as LIMN
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026Score 2/30
$0.04+0.00 (0.00%)

Close on Oct 30, 2026Market cap $189.39MP/E –Yield –

StockData Score

Prices as of Oct 30, 2026How the score works

Value0Growth0Performance0Health2Dividend0

Weak2 of 30 checks passed

Liminatus Pharma passes 2 of the 30 checks behind our score; 23 could not be run for lack of data and count as not passed. Each dot in the shape is one check — hover it for the numbers.

Valuation
0/6
Growth
0/6
Past performance
0/6
Financial health
2/6
Dividend
0/6

What stands out

  • Low bankruptcy risk

    The Altman Z-score is 15.77; above 3 is the safe zone and below 1.8 the distress zone.

  • Short-term assets cover short-term debts

    Current assets are 1.12 times current liabilities.

What to watch

  • High debt

    Debt is 480% of shareholders' equity, above the 40% we consider low.

  • Interest not well covered

    Operating income covers interest expense -53.8 times; we look for at least 5.

  • Debt not well covered by cash flow

    Operating cash flow over the last twelve months equals -275% of total debt; we look for at least 20%.

  • P/B above the industry

    Liminatus Pharma's price-to-book of 630.02 is above the Drugs median of 2.31.

Valuation0/6

  • P/E against its history

    Not enough price and earnings history to compare.

  • P/E against the industry

    Needs positive earnings and enough profitable companies in the industry.

  • EV/EBITDA against its history

    Needs positive EBITDA and price history.

  • P/B above the industry

    Liminatus Pharma's price-to-book of 630.02 is above the Drugs median of 2.31.

  • Price against fair value

    We could not estimate a fair value: it needs at least two valuation methods with positive inputs.

  • Margin of safety

    Depends on the fair value estimate.

Growth0/6

  • Revenue growth over 3 years

    Needs three years of positive revenue.

  • EPS growth over 3 years

    Needs positive EPS three years ago and today.

  • Earnings acceleration

    Needs positive net income now, a year ago and five years ago.

  • Growth against the industry

    Needs revenue for this year and last.

  • Company guidance

    No outlook found in earnings releases from the last twelve months.

  • Gross margin trend

    This company does not report gross profit.

Past performance0/6

  • Return on equity

    Needs positive equity and five years of results.

  • Return on invested capital

    Needs operating income and invested capital.

  • Return on equity against the industry

    Needs positive equity.

  • Earnings over 5 years

    Needs positive net income five years ago and in the latest year.

  • Net margin against its history

    Needs five years of revenue and net income.

  • Net margin against the industry

    Needs revenue and net income.

Financial health2/6

  • High debt

    Debt is 480% of shareholders' equity, above the 40% we consider low.

  • Debt trend

    Needs a balance sheet from five years ago with positive equity.

  • Debt not well covered by cash flow

    Operating cash flow over the last twelve months equals -275% of total debt; we look for at least 20%.

  • Interest not well covered

    Operating income covers interest expense -53.8 times; we look for at least 5.

  • Short-term assets cover short-term debts

    Current assets are 1.12 times current liabilities.

  • Low bankruptcy risk

    The Altman Z-score is 15.77; above 3 is the safe zone and below 1.8 the distress zone.

Dividend0/6

  • No dividend

    Liminatus Pharma has not paid a dividend in the last twelve months.

  • Yield against Treasuries

    No dividend.

  • Yield against the market

    No dividend.

  • Dividend stability

    No dividend.

  • Earnings cover

    No dividend.

  • Cash-flow cover

    No dividend.

Scores of similar companies

Fair value

How we estimate it

We don't publish a fair value for Liminatus Pharma. It needs a US-dollar share price, at least two valuation methods with positive inputs (earnings, EBITDA, book value or sales) and, for companies with several share classes, classes that trade at the same price.

Valuation over time

Using the earnings and balance sheet published at each date, not today's.

An estimate from reported numbers and market multiples, not a price target or investment advice. It can be far off for companies whose profits are about to change sharply.

Market risk

From the past year of daily prices.

Liquidity

High risk

Average value traded per day
$92.16K
Value traded per 1% price move
$24.51K

Downside

High risk

Typical loss in a bad month
76.2%
Volatility (annualized)
178%
Sharpe ratio, 1 year
-0.57
Beta to the S&P 500 (5Y)
0.72

Typical bad-month loss, week by week

25%: high

Margins need revenue and profit figures

This company does not report the lines needed to calculate margins.